Equities

Stella Pharma Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4888:TYO

Stella Pharma Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)419.00
  • Today's Change38.00 / 9.97%
  • Shares traded1.82m
  • 1 Year change-18.64%
  • Beta2.0859
Data delayed at least 15 minutes, as of Feb 18 2026 03:37 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.

  • Revenue in JPY (TTM)968.76m
  • Net income in JPY-279.32m
  • Incorporated2007
  • Employees43.00
  • Location
    Stella Pharma Corp3-2-7, Koraibashi, Chuo-kuOSAKA-SHI 541-0043JapanJPN
  • Phone+81 647071516
  • Fax+81 647072077
  • Websitehttps://stella-pharma.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nippon Chemiphar Co Ltd32.52bn545.00m7.62bn855.0011.850.3373.720.2344151.00151.009,009.805,309.460.62331.982.7538,035,090.001.040.67941.440.968626.1928.431.681.041.34--0.478555.165.930.5075263.33-7.5832.850.00
CellSource Co Ltd3.71bn10.66m7.77bn148.00783.471.2937.202.090.50030.5003186.84303.580.52655.9111.3125,077,400.000.151210.680.161311.8956.2464.880.287214.3711.7916.090.009320.88-14.7814.87-95.52-47.768.90--
COSMO BIO COMPANY, LIMITED10.77bn337.00m7.90bn174.0022.100.791215.780.734259.1459.141,893.021,651.940.8836.533.57--2.744.413.245.2434.3935.523.104.884.46--0.00250.687.265.8828.63-12.9434.028.02
Solasia Pharma KK429.00m-876.00m8.08bn23.00--4.51--18.83-3.79-3.791.816.650.24471.842.13---49.96-64.76-58.36-79.6048.4858.61-204.20-297.255.70-61.500.0514--35.76-1.1354.87------
K Pharma Inc0.00-993.23m8.46bn17.00--6.69-----85.59-85.590.00109.000.000.00-----37.53---38.74----------28.29-1,982.810.5424-------17.34------
Wakamoto Pharmaceutical Co Ltd9.29bn298.60m11.11bn286.0037.080.915715.001.208.608.60267.77348.390.60061.623.0632,493,160.001.93-0.06782.22-0.078147.7048.653.21-0.12462.42--0.0082--0.6595-6.53-40.86--21.87--
Stella Pharma Corp968.76m-279.32m12.66bn43.00--4.70--13.07-8.21-8.2128.4779.220.19660.09442.9122,529,260.00-5.67-16.41-5.96-18.1987.8887.03-28.83-176.1613.81-45.690.226--256.62--81.56---21.34--
CellSeed Inc83.68m-1.10bn13.31bn38.00--10.09--159.04-31.83-31.832.4135.670.04090.65613.81---54.00-46.88-59.08-50.9551.0953.64-1,319.46-593.855.81--0.0949---56.71-15.95-28.41--21.04--
Immuno-Biological Laboratories Co., Ltd.1.03bn363.89m15.14bn58.0041.598.5939.5914.6739.0739.07110.76189.250.54560.86034.8117,786,030.0019.25-4.9622.46-5.7770.3562.7035.27-11.273.962,702.080.0947--18.7110.9533.40------
ReproCell Inc2.52bn-324.61m15.45bn99.00--1.76--6.13-3.42-3.4226.6392.820.23284.155.9225,450,770.00-3.00-4.09-3.63-4.4749.3543.75-12.88-13.664.93--0.00--22.7419.94428.65---6.31--
TAIKO PHARMACEUTICAL CO LTD6.40bn923.00m15.60bn214.0016.761.8213.122.4418.3718.37127.34169.510.50801.772.62--7.34-18.999.32-24.0454.4240.2014.44-46.312.72--0.0874--1.67--2.78------
CanBas Co Ltd (Parent)0.00-1.25bn17.39bn14.00--7.31-----64.11-64.110.00120.620.00----0.00-44.48-57.04-46.19-62.13-------4,587.85---566.180.00------4.27------
StemRIM Inc0.00-1.90bn18.62bn45.00--2.71-----30.56-30.560.00109.730.00----0.00-24.08-12.71-24.55-12.88-------167.3547.00--0.00------4.59---22.11--
Data as of Feb 18 2026. Currency figures normalised to Stella Pharma Corp's reporting currency: Japanese Yen JPY

Institutional shareholders

0.33%Per cent of shares held by top holders
HolderShares% Held
Amova Asset Management Co., Ltd.as of 14 Nov 202565.50k0.19%
Simplex Asset Management Co., Ltd.as of 05 Feb 202645.20k0.13%
Data from 31 Dec 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.